Quantcast

Latest Monoclonal antibodies Stories

2014-08-20 08:27:31

MUMBAI, August 20, 2014 /PRNewswire/ -- Glenmark Pharmaceuticals S.A. (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), announces the discovery and initiation of IND enabling studies of a novel clinical development candidate, GBR 1302, a HER2xCD3 bispecific antibody. GBR 1302 was discovered and developed by the Glenmark Biologics Research Centre located in La Chaux-de-Fonds, Switzerland. GBR 1302 is based on Glenmark's innovative BEAT antibody...

2014-08-14 23:11:39

BioScience Laboratories, Inc. can now screen psoriasis drug formulations in their Skin Technology Center utilizing an in-vitro human psoriasis tissue model. Bozeman, MT (PRWEB) August 14, 2014 Psoriasis is an immune-mediated disease that results in deep skin cells rising rapidly to the surface in just days, rather than the normal month. Extra skin cells build up and form thick, silvery scales and dry red patches that often present on the elbows, knees, scalp, back, face, palms and feet of...

2014-08-14 23:02:59

The North American ion exchange chromatography reagents report defines and segments the concerned market in North America with analysis and forecast of revenue. http://www.micromarketmonitor.com/market/north-america-ion-exchange-chromatography-reagents-7680860258.html (PRWEB) August 14, 2014 The North American ion exchange chromatography reagents report defines and segments the concerned market in North America with analysis and forecast of revenue. The ion exchange chromatography...

2014-08-14 08:29:14

-- Anti-EphA3 Agents Inhibit Tumor Growth by Disrupting or Destroying the Tumor Microenvironment: Malignant Stem Cells, Stromal Cells, and New Tumor Vasculature -- SOUTH SAN FRANCISCO, Calif., Aug. 14, 2014 /PRNewswire/ -- KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO) today announced the publication of preclinical findings describing EphA3 as a novel target expressed by a broad range of human tumors, and whose activation can lead to the selective disruption of the tumor microenvironment and...

2014-08-11 08:28:49

SAN DIEGO, Aug. 11, 2014 /PRNewswire/ -- Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, today announced that Scott Pancoast, president and CEO, will present at the 34th Annual Canaccord Genuity Growth Conference on Wednesday, August 13, 2014 at 5:00 p.m. Eastern Time in Boston. The live webcast presentation and replay will be available by visiting the Investor section of the Lpath website at www.Lpath.com. About Lpath San Diego-based Lpath,...

2014-08-08 16:23:14

SAN DIEGO, Aug. 8, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and its associated pain, today announced the addition of industry veteran Douglas Ebersole to its Board of Directors. Mr. Ebersole has over 25 years of broad business experience in industry as well as from consulting in a number of advisory roles, including as a former partner in a Silicon Valley law firm....

2014-08-07 20:24:36

Leukotuximab is a novel, first-in-class Leukemia-specific mAb targeting JL-1 SHENYANG, China, Aug. 7, 2014 /PRNewswire/ -- 3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with DiNonA Inc. for the development, manufacturing and marketing of Leukotuximab, an anti JL-1 antibody for acute leukemia (AL), including acute myelocytic...

2014-08-07 12:28:48

Biogen Idec's Tecfidera is Forecast to Overtake Teva's Copaxone Franchise as the U.S. Market Leader by 2015, According to Findings from Decision Resources Group BURLINGTON, Mass., Aug. 7, 2014 /PRNewswire/ -- Decision Resources Group finds that the forecast launch of Biogen Idec's Plegridy, Roche/Genentech's ocrelizumab, Biogen Idec/AbbVie's daclizumab, Teva/Active Biotech's Nerventra and Receptos' RPC-1063, coupled with the expected U.S. approval of Genzyme/Sanofi/Bayer HealthCare's...

2014-08-05 08:35:59

LONDON, Aug. 5, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Systemic Psoriasis Therapeutics in Major Developed Markets to 2020 - Continued Uptake of Biologics and Novel Pipeline Drugs to Drive Growthhttp://www.reportbuyer.com/pharma_healthcare/treatments/systemic_psoriasis_therapeutics_major_developed_markets_2020_continued_uptake_biologics_novel_pipeline_drugs_drive_growth.htmlSystemic Psoriasis Therapeutics in Major Developed Markets to 2020 -...

2014-08-05 08:34:27

Supports progression of this first-in-class anti-TLR4 monoclonal antibody into clinical proof of concept study as a potential personalized medicine for rheumatoid arthritis GENEVA, August 5, 2014 /PRNewswire/ -- Novimmune SA, a company focused on the discovery and development of antibody-based drugs to benefit patients with inflammatory, auto-immune disorders, and cancer announces today the completion of a comprehensive Phase I clinical trial investigating the pharmacokinetics,...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'